Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Susceptibility

In Vitro Activity of Omadacycline against Chlamydia pneumoniae

Stephan A. Kohlhoff, Natalia Huerta, Margaret R. Hammerschlag
Stephan A. Kohlhoff
aDepartment of Pediatrics, Division of Pediatric Infectious Diseases, State University of New York Downstate Medical Center, Brooklyn, New York, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Natalia Huerta
aDepartment of Pediatrics, Division of Pediatric Infectious Diseases, State University of New York Downstate Medical Center, Brooklyn, New York, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Margaret R. Hammerschlag
aDepartment of Pediatrics, Division of Pediatric Infectious Diseases, State University of New York Downstate Medical Center, Brooklyn, New York, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/AAC.01907-18
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

The in vitro activities of omadacycline, azithromycin, doxycycline, moxifloxacin, and levofloxacin were tested against 15 isolates of Chlamydia pneumoniae. The minimum inhibitory concentration at which 90% of the isolates of C. pneumoniae were inhibited by omadacycline was 0.25 μg/ml (range, 0.03 to 0.5 μg/ml).

INTRODUCTION

Chlamydia pneumoniae is a frequent cause of community-acquired respiratory infections, including pneumonia and bronchitis, in adults and children (1). Antibiotics commonly used to treat C. pneumoniae respiratory infections include macrolides, quinolones, and tetracyclines, specifically doxycycline (2).

Omadacycline (PTK 0796) is a new aminomethylcycline with potent in vitro antibacterial activity against a broad range of bacteria that cause respiratory infections, including Streptococcus pneumoniae (3) and Mycoplasma pneumoniae (4). We compared the in vitro activity of omadacycline with those of azithromycin, doxycycline, moxifloxacin, and levofloxacin against 15 isolates of C. pneumoniae.

Tested isolates of C. pneumoniae included 2 isolates from ATCC (Manassas, VA), i.e., TW-183 (VR-2282) and CM-1 (VR-1360), and 13 human isolates from patients with community-acquired pneumonia, including bronchoalveolar lavage specimens from patients with pneumonia from the United States. Omadacycline, azithromycin, levofloxacin, moxifloxacin, and doxycycline were provided as powders and solubilized according to the manufacturers’ instructions. Sterile stock solutions of 1,280 μg/ml were made and frozen at −80°C. Aliquots of the stock drug suspensions were diluted each time the assay was run. C. pneumoniae isolates were expanded to concentrations of 107 to 108 inclusion-forming units (IFU) per milliliter by serial passage in tissue culture with antibiotic-free medium as previously described (5). Isolates were purified by centrifugation at 500 rpm to bring down the cell debris. The chlamydia-containing supernatant was pelleted at 17,000 × g for 1 h. The pellet containing the chlamydia was then resuspended in sucrose phosphate glutamate (SPG) and centrifuged through a discontinuous renografin gradient. The chlamydial elementary body (EB)-containing band was then washed 3 times and resuspended in SPG. The titers of the EB suspension were determined in HEp-2 cells (ATCC CCL-23).

Susceptibility testing of C. pneumoniae isolates was performed in cell culture by using HEp-2 cells grown in 96-well microtiter plates as previously described (6). Each well was inoculated with 0.2 ml of the test strain diluted to yield 104 IFU/ml; the plates were centrifuged at 1,700 × g for 1 h and incubated at 35°C for 1 h. Wells were then aspirated and overlaid with medium containing 1 μg/ml of cycloheximide and serial 2-fold dilutions of the test drugs. After incubation at 35°C for 72 h, cultures were fixed and stained for inclusions with fluorescein-conjugated antibody to the chlamydial lipopolysaccharide genus-specific antigen (Pathfinder Chlamydia Culture Confirmation System; Bio-Rad, Hercules, CA). The MIC was the lowest antibiotic concentration at which no inclusions were seen. The minimal bactericidal concentration (MBC) was determined by aspirating the antibiotic-containing medium, washing wells twice with phosphate-buffered saline, and adding antibiotic-free medium. The infected cells were frozen at −70°C, thawed, passed onto new cells, incubated for 72 h, and then fixed and stained as described above. The MBC was the lowest antibiotic concentration that resulted in no inclusions after passage. All tests were run in duplicate. Positive (infection ± equal volumes drug carrier without active drug added) and negative (addition of medium ± active drug, not containing any bacteria) infection controls were included with each experiment.

The MICs and MBCs for C. pneumoniae are shown in Table 1. The MIC90 of C. pneumoniae isolates to omadacycline was 0.25 μg/ml (range, 0.03 to 0.5 μg/ml). The MBC90 of the isolates to omadacycline was 0.5 μg/ml (range, 0.6 to 0.5 μg/ml).

View this table:
  • View inline
  • View popup
TABLE 1

Activities of omadacycline and comparators against 15 isolates of C. pneumoniae

The in vitro activity of omadacycline against C. pneumoniae infection was comparable with the other antibacterial drugs tested, including doxycycline. The MIC90 and MBC90 were within 2 dilutions of the other agents. However, in vitro activity may not necessarily predict microbiological efficacy in vivo against C. pneumoniae infection (2).

The in vitro activity of omadacycline is comparable to those of several antibiotics with proven clinical efficacy. The results presented in this report therefore suggest that omadacycline would be effective for the treatment of infections due to C. pneumoniae isolates, depending on the concentrations achieved at the site of infection. Omadacycline has been demonstrated to achieve high, sustained concentrations in plasma, epithelial lining fluid, and alveolar cells, suggesting that it may be effective in the treatment of pulmonary infections, including those caused by intracellular organisms such as C. pneumoniae (7). A recent phase 3 trial found that a single daily dose of omadacycline was noninferior to moxifloxacin for treatment of community-acquired pneumonia caused by C. pneumoniae, based on clinical response (8).

ACKNOWLEDGMENTS

This study was supported in part by a grant from Paratek Pharmaceuticals, Inc. The funders had no role in study design, data collection, and interpretation or the decision to submit the work for publication.

FOOTNOTES

    • Received 5 September 2018.
    • Returned for modification 1 October 2018.
    • Accepted 25 November 2018.
    • Accepted manuscript posted online 3 December 2018.
  • Copyright © 2019 American Society for Microbiology.

All Rights Reserved.

REFERENCES

  1. 1.↵
    1. Hammerschlag MR,
    2. Kohlhoff SA,
    3. Gaydos CA
    . 2014. Chlamydia pneumoniae, p 2174–2182. In Mandell GL, Bennett JE, Dolin R (ed), Principles and Practice of Infectious Diseases, 8th ed. Elsevier, Inc., Philadelphia, PA.
  2. 2.↵
    1. Kohlhoff SA,
    2. Hammerschlag MR
    . 2015. Treatment of chlamydial infections: 2014 update. Expert Opin Pharmacother 16:205–212. doi:10.1517/14656566.2015.999041.
    OpenUrlCrossRef
  3. 3.↵
    1. Pfaller MA,
    2. Rhomberg PR,
    3. Huband MD,
    4. Flamm RK
    . 2018. Activity of omadacycline tested against Streptococcus pneumoniae from a global surveillance program. Diagn Microbiol Infect Dis 90:143–147. doi:10.1016/j.diagmicrobio.2017.10.010.
    OpenUrlCrossRef
  4. 4.↵
    1. Waites KB,
    2. Crabb DM,
    3. Lui Y,
    4. Duffy LB
    . 2016. In vitro activities of omadacycline (PTK 0796) and other antimicrobial agents against human mycoplasmas and ureaplasmas. Antimicrob Agents Chemother 60:7502–7504. doi:10.1128/AAC.01734-16.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Kohlhoff SA,
    2. Huband MD,
    3. Hammerschlag MR
    . 2014. In vitro activity of AZD0914, a novel DNA gyrase inhibitor, against Chlamydia trachomatis and Chlamydia pneumoniae. Antimicrob Agents Chemother 58:7595–7596. doi:10.1128/AAC.03920-14.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    1. Roblin PM,
    2. Dumornay W,
    3. Hammerschlag MR
    . 1992. Use of HEp-2 cells for improved isolation and passage of Chlamydia pneumoniae. J Clin Microbiol 30:1968–1971.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Gotfried MH,
    2. Horn K,
    3. Garrity-Ryan L,
    4. Villano S,
    5. Tzanis E,
    6. Chitra S,
    7. Manley TSK,
    8. Rodvold KA
    . 2018. Comparison of omadacycline and tigecycline pharmacokinetics in the plasma, epithelial lining fluid, and alveolar cells of healthy adults. Antimicrob Agents Chemother 61:e01135-17. doi:10.1128/AAC.01135-17.
    OpenUrlCrossRef
  8. 8.↵
    1. Stets R,
    2. Popescu M,
    3. Gonong J,
    4. Mitha I,
    5. Nseir W,
    6. Madej A,
    7. Kirsch C,
    8. Das A,
    9. Garrity-Ryan L,
    10. Steenbergen JN,
    11. Manley A,
    12. Eckburg PB,
    13. Villano S,
    14. Tzanis E,
    15. McGovern P,
    16. Loh E
    . 2017. A phase 3, randomized, double-blind, multi-center study to compare the safety and efficacy of IV to oral omadacycline to moxifloxacin for the treatment of adult patients with CABP (the OPTIC study). Open Forum Infect Dis 4(Suppl 1):S543. doi:10.1093/ofid/ofx163.1413.
    OpenUrlCrossRef
View Abstract
PreviousNext
Back to top
Download PDF
Citation Tools
In Vitro Activity of Omadacycline against Chlamydia pneumoniae
Stephan A. Kohlhoff, Natalia Huerta, Margaret R. Hammerschlag
Antimicrobial Agents and Chemotherapy Jan 2019, 63 (2) e01907-18; DOI: 10.1128/AAC.01907-18

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
In Vitro Activity of Omadacycline against Chlamydia pneumoniae
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
In Vitro Activity of Omadacycline against Chlamydia pneumoniae
Stephan A. Kohlhoff, Natalia Huerta, Margaret R. Hammerschlag
Antimicrobial Agents and Chemotherapy Jan 2019, 63 (2) e01907-18; DOI: 10.1128/AAC.01907-18
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • INTRODUCTION
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

Chlamydia pneumoniae
omadacycline
tetracyclines

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596